Gene · 676
BRDT: bromodomain testis associated
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. BRDT: bromodomain testis associated. Genes, record 676. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/676
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q58F21 | Bromodomain testis-specific protein | 947 | 21 | Ensembl, GeneID, HGNC |
Source UniProt
Patents50
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 39250 | Q58F21 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 39252 | Q58F21 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 39253 | Q58F21 | Espacenet |
| WO 2025243001 A1 | 2025-11-27 | 4 | Q58F21 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 7992 | Q58F21 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 7992 | Q58F21 | Espacenet |
| JP 2025062604 A | 2025-04-14 | 9889 | Q58F21 | Espacenet |
| JP 2025062604 A | 2025-04-14 | 9892 | Q58F21 | Espacenet |
| EP 4487869 A2 | 2025-01-08 | 116 | Q58F21 | Espacenet |
| JP 2024097033 A | 2024-07-17 | 165 | Q58F21 | Espacenet |
1 to 10 of 50
See all 50 patentsDrugs6
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| APABETALONE | CHEMBL2393130 | Bromodomain and extra-terminal motif (BET) inhibitor | INHIBITOR | ChEMBL |
| BIRABRESIB | CHEMBL3581647 | Bromodomain and extra-terminal motif (BET) inhibitor | INHIBITOR | ChEMBL |
| EZOBRESIB | CHEMBL4297458 | Bromodomain and extra-terminal motif (BET) inhibitor | INHIBITOR | ChEMBL |
| MOLIBRESIB | CHEMBL1232461 | Bromodomain and extra-terminal motif (BET) inhibitor | INHIBITOR | ChEMBL |
| PELABRESIB | CHEMBL4303404 | Bromodomain and extra-terminal motif (BET) inhibitor | INHIBITOR | ChEMBL |
| RO-6870810 | CHEMBL4297423 | Bromodomain and extra-terminal motif (BET) inhibitor | INHIBITOR | ChEMBL |
Trials42
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07357727 | PELABRESIB | PHASE3 | ClinicalTrials.gov | |
| NCT07340138 | PELABRESIB | PHASE1 | ClinicalTrials.gov | |
| NCT06590324 | APABETALONE | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT06401356 | PELABRESIB | PHASE3 | ClinicalTrials.gov | |
| NCT05372354 | EZOBRESIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT04915300 | APABETALONE | PHASE2 | ClinicalTrials.gov | |
| NCT04894266 | APABETALONE | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT04817007 | EZOBRESIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT04603495 | PELABRESIB | PHASE3 | 2024-10-28 | ClinicalTrials.gov |
| NCT03936465 | EZOBRESIB | PHASE1 | ClinicalTrials.gov |
1 to 10 of 42
See all 42 trialsNIH grants1,094
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | BRDT papers | Newest fiscal year |
|---|---|---|---|
| P30CA076292 | Moffitt Cancer Center Support Grant | 10 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 8 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 7 | 2025 |
| P30CA046592 | University of Michigan Rogel Cancer Center Support Grant 2023-2028 | 7 | 2025 |
| P01CA066996 | Development of Novel Therapeutic Strategies in Human Leukemias | 6 | 2025 |
| P50CA186786 | Michigan Prostate SPORE 2025-2030 | 6 | 2025 |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 5 | 2025 |
| R01CA124633 | Pathogenesis and Treatment of NUT midline carcinoma | 5 | 2025 |
| R35GM140837 | Chemical Probe Development for Epigenetic Complexes Enabled by Protein-Observed 19F NMR | 5 | 2025 |
| P30AI027763 | UCSF-Bay Area Center for AIDS Research | 4 | 2025 |
1 to 10 of 1,094Source NIH's project files
See all 1,094 nih grantsPapers1,261
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| MAPK signaling links BRD2 chromatin occupancy to PI3K/AKT inhibitor sensitivity. | bioRxiv | 2026 | 42818240 | PubTator, text mining | PubMed |
| Integrative Analysis Identified an Eight-Gene Risk Signature Linked to CDK7 and Explored Its Association with HCC Progression via RelA Phosphorylation. | Oncol Res | 2026 | 42500561 | PubTator, text mining | PubMed |
| BRD4: From molecular understanding to therapeutics development. | Mol Cell | 2026 | 42492506 | PubTator, text mining | PubMed |
| Unraveling the layers of epigenetic control in respiratory antiviral defense. | J Virol | 2026 | 42159289 | PubTator, text mining | PubMed |
| Proximity Binding Assay for PROTAC Ternary Complex Analysis. | ACS Sens | 2026 | 42011828 | PubTator, text mining | PubMed |
| Meiotic prophase I disruption as a strategy for nonhormonal male contraception using small-molecule inhibitor JQ1. | Proc Natl Acad Sci U S A | 2026 | 41945432 | PubTator, text mining | PubMed |
| The histone acylation network: emerging therapeutic targets for remodeling the epigenetic landscape in pancreatic ductal adenocarcinoma. | Cell Oncol (Dordr) | 2026 | 41874858 | PubTator, text mining | PubMed |
| Clonal dynamics of HIV-infected and uninfected T cells. | EBioMedicine | 2026 | 41855971 | PubTator, text mining | PubMed |
| Quinoxaline Derivatives in Cancer Therapy: Insights into Mechanisms of Action and Therapeutic Applications. | Biomol Ther (Seoul) | 2026 | 41755772 | PubTator, text mining | PubMed |
| Redox-Genomic Crosstalk: Linking Oxidative Stress, Sperm DNA Fragmentation, and Epigenetics in Personalized Management of Male Infertility. | J Pers Med | 2026 | 41745372 | PubTator, text mining | PubMed |
1 to 10 of 1,261
See all 1,261 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/676
GET https://conductscience.org/api/genes/v1/676/patents?page=2